BJH - 2021, issue SPECIAL, january 2021
prof. M.V. Mateos
Multiple myeloma (MM) is a clonal plasma cell malignancy affecting a predominantly elderly population. The continued development of newer therapies with novel mechanisms of action has reshaped the treatment paradigm of this disorder in the last two decades, leading to a significantly improved prognosis. Immune-based therapies, including monoclonal antibodies, and more recently also adoptive cellular therapies have emerged as therapeutic strategies in MM. During her lecture at the 2021 BHS GAM, Prof. Maria-Victoria Mateos gave an overview of the current state of affairs related to immune related therapies in MM.
Read moreTo provide the best experiences, we and our partners use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us and our partners to process personal data such as browsing behavior or unique IDs on this site and show (non-) personalized ads. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Click below to consent to the above or make granular choices. Your choices will be applied to this site only. You can change your settings at any time, including withdrawing your consent, by using the toggles on the Cookie Policy, or by clicking on the manage consent button at the bottom of the screen.